Compare UBXG & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBXG | ICCC |
|---|---|---|
| Founded | 2018 | 1982 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 55.5M |
| IPO Year | 2024 | 1987 |
| Metric | UBXG | ICCC |
|---|---|---|
| Price | $1.96 | $6.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.2K | ★ 34.1K |
| Earning Date | 12-22-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $29,674,534.00 | $27,769,304.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $23.82 |
| Revenue Growth | N/A | ★ 16.49 |
| 52 Week Low | $1.62 | $4.28 |
| 52 Week High | $4.64 | $7.60 |
| Indicator | UBXG | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 58.33 |
| Support Level | $1.93 | $5.56 |
| Resistance Level | $2.08 | $7.12 |
| Average True Range (ATR) | 0.12 | 0.36 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 11.11 | 40.49 |
U-BX Technology Ltd focuses on providing value-added services using artificial intelligence-driven technology to businesses in the insurance industry, including insurance carriers and brokers. Its main offerings include three services/products: digital promotion services, risk assessment services, and value-added bundled benefits. The PRC operating entities help their institutional clients gain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or clients' promotion time on these channels. U-BX Beijing developed a unique algorithm named the Magic Mirror. The majority of revenue comes from digital promotion services. Geographically, all of the company's revenue is derived from Mainland China.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.